REDWOOD CITY, Calif.,
Feb. 4, 2015 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that Timothy E Morris,
Chief Financial Officer, will present a company overview and update
at the 17th Annual BIO CEO & Investor Conference. Details of
the presentation are as follows:
BIO CEO & Investor Conference
Date: Monday, February 9th
Location: The Waldorf Astoria New York
Presentation Time: 11:30am ET,
8:30am PT
The presentation will be webcast live and can be accessed
through the Investors page at www.acelrx.com. For those not
available to listen to the live broadcast, a replay will be
archived for 90 days and available through the Investors page on
www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain. AcelRx's lead product candidate, Zalviso, is designed
to improve the management of moderate-to-severe acute pain in adult
patients in the hospital setting by utilizing a high therapeutic
index opioid, through a non-invasive delivery route via a
pre-programmed, patient-controlled analgesia device. AcelRx has
announced positive results from each of the three completed Phase 3
clinical trials for Zalviso, and has submitted an NDA to the FDA
seeking approval for Zalviso in the treatment of moderate-to-severe
acute pain in adult patients in the hospital setting and on
July 25th, received a Complete
Response Letter from the FDA. AcelRx plans to initiate a Phase 3
clinical trial for ARX-04, a product candidate for the treatment of
moderate-to-severe acute pain in a medically supervised setting.
The Company has two additional pain treatment product candidates,
ARX-02 and ARX-03, which have completed Phase 2 clinical
development. For additional information about AcelRx's clinical
programs, please visit www.acelrx.com.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to the company's
Zalviso NDA and the Complete Response Letter, or CRL, the recent
meeting held with the FDA to discuss the CRL, our plans to address
the issues raised in the CRL, our anticipated resubmission of the
Zalviso NDA to the FDA, including the scope of the resubmission and
the timing of the resubmission and FDA review time, timing and
potential approval of the MAA for Zalviso in Europe, planned initiation of the Phase 3
clinical trial for ARX-04, and the therapeutic and commercial
potential of AcelRx Pharmaceuticals' product candidates, including
Zalviso. These forward-looking statements are based on AcelRx
Pharmaceuticals' current expectations and inherently involve
significant risks and uncertainties. AcelRx Pharmaceuticals' actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, risks
related to: AcelRx Pharmaceuticals' ability to receive regulatory
approval for Zalviso; any delays or inability to obtain and
maintain regulatory approval of its product candidates, including
Zalviso, in the United States and
Europe; AcelRx's ability to build
an effective commercial organization; its ability to obtain
sufficient financing to commercialize Zalviso and proceed with
clinical development of ARX-04; the success, cost and timing of all
product development activities and clinical trials, including the
planned Phase 3 ARX-04 trial; the market potential for its product
candidates; and other risks detailed in the "Risk Factors" and
elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange
Commission filings and reports, including its Quarterly Report on
Form 10-Q filed with the SEC on November 10,
2014. AcelRx Pharmaceuticals undertakes no duty or
obligation to update any forward-looking statements contained in
this release as a result of new information, future events or
changes in its expectations.
Logo -
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-bio-ceo--investor-conference-300030437.html
SOURCE AcelRx Pharmaceuticals, Inc.